Respiratory Diseases

The long acting antibody combination reduced risk of severe disease or all-cause mortality by 50% in outpatients with high-risk comorbidities.

Two doses of the Pfizer COVID-19 vaccine also showed sustained efficacy of 93% against Delta-related hospital admission.

Janssen's investigational vaccine showed efficacy of up to 80% in preventing RSV-mediated lower respiratory tract infections in older adults.

COVID-19 case increases in the past 7 days range from 100% to 3.16% among the 10 states with the most significant rises. Is your state among these?

The albuterol/budesonide combination significantly reduced the risk of severe exacerbations and improved lung function in mild-to-moderate asthma.

Ivermectin has shown no clinical benefit for the many viral infections it has been studied in - including COVID-19. Why are patients buying it and physicians prescribing it?

A new study found several risk factors associated with severe adult-onset asthma, including smoking, NSAID-exacerbated respiratory disease, and sibling count.

FDA approval of mezopelumab follows the phase 3 SYNAPSE trial in which the anti-Il-5 monoclonal antibody reduced by 57% the need for nasal polyp surgery.

Tezepelumab, a novel human monoclonal antibody that shows promise to reduce exacerbations across asthma phenotypes, was granted FDA Priority Review.

Four major cardiology organizations stand behind increased government action to eradicate tobacco use worldwide. Click here for a summary of why, why now, and how.

Patients with asthma or COPD living in areas with high levels of air pollution are at an increased risk of hospitalization if they contract COVID-19, suggests a new pilot study.

Individuals vaccinated against influenza were 24% less likely to be infected with COVID-19 than those who did not get the flu shot, according to Michigan Medicine researchers.

Research into biologic therapy for asthma and COPD has been both successful and frustrating. Find out what you know about the progress with these 8 questions.

Using metabolomic profiling from more than 11 000 individuals, researchers identified common pathways linking seemingly unrelated diseases that often co-occur.

Post-hoc analysis of the phase 3 KRONOS study concluded that the benefits in COPD exacerbation seen were not driven by the small subgroup with a prior history of exacerbations.

No biologic agent is approved to treat COPD, but progress is being made. Key developments of the past few years are summarized in this brief slideshow.

Hyaluronan represents a new class of biologic that significantly improves lung health in patients with severe COPD.

Most diagnoses of COPD are made in the primary care setting. Try these 6 questions to see what you know about the essentials of the differential diagnosis.

Distinguishing asthma and COPD can at times be problematic and the asthma-COPD overlap picture is even less clear. Check your recall of GINA/GOLD guidelines on all 3.

AHA 2020 Virtual Scientific Sessions: Cumulative exposure, exposure intensity, and number of household smokers in childhood all impact adult heart function, study authors found.

The novel monoclonal antibody could bring relief to millions of persons with severe, uncontrolled asthma, including those with a low eosinophil phenotype.

Use of the myCOPD app after hospitalization for acute COPD exacerbation reduced subsequent exacerbations by nearly 50%, according to study authors.

In COPD patients, a new study found no association between lung function decline and individual CVD outcomes, but disease exacerbations and dyspnea were implicated.

More than 10% of those who develop severe COVID-19 have misguided antibodies that derail the immune response, according to new research.

Long-acting muscarinic antagonists, recommended as add-on therapy for asthma, are too often used as monotherapy and are linked with severe exacerbations, a new study finds.

New research presented at the virtual European Respiratory Society International Congress showed "social smokers" are more than twice as likely to die of lung disease vs non-smokers.

Treatment guidelines on COVID-19 from the NIH were updated today based on data from clinical trials of hydroxychloroquine, ivermectin, and IL-6 inhibitors.

The ACIP, once more, revised its recommendations for administration of pneumococcal vaccination among adults aged ≥65 years. Is there a lesson learned here?

A new survey found adolescents who have ever used e-cigarettes are 5-times more likely to receive a COVID-19 diagnosis. More results at-a-glance in our new slideshow.